XI Jornada Mineira de Reumatologia
1º Dia - 8/1/19
2º Dia - 8/2/19
3º Dia - 8/3/19

Manejo da AIJ 2019: novas perspectivas terapêuticas Voltar

Maria Vitoria Padua De Quintero

Mesa Redonda: Pediatria - Presidente: Rejane Pinheiro damasceno; Moderador: Anna Carolina faria Moreira Gosmes Tavares

Artigo Autor(es) Referência
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Ringold Sarah, Angeles-Han Sheila T, Beukelman Timothy, Lovell Daniel, Cuello Carlos A, Becker Mara L, Colbert Robert A, Feldman Brian M, Ferguson Polly J, Gewanter Harry, Guzman Jaime, Horonjeff Jennifer, Nigrovic Peter A, Ombrello Michael J, Passo Murray H, Stoll Matthew L, Rabinovich C Egla, Schneider Rayfel, Halyabar Olha, Hays Kimberly, Shah Amit Aakash, Sullivan Nancy, Szymanski Ann Marie, Turgunbaev Marat, Turner Amy, Reston James Arthritis & rheumatology (Hoboken, N.J.). 2019 06; 71(06):846-863. doi: 10.1002/art.40884. pii: .
A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis. Henderson Lauren A Arthritis & rheumatology (Hoboken, N.J.). 2019 07; 71(07):1030-1033. doi: 10.1002/art.40867. pii: .
Cyclosporine for Systemic Onset Juvenile Idiopathic Arthritis: Current Stand and Future Directions. Bagri Narendra Kumar Indian journal of pediatrics. 2019 07; 86(07):576-577. doi: 10.1007/s12098-019-02985-6. pii: .
Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. Saccomanno Benedetta, Tibaldi Jessica, Minoia Francesca, Bagnasco Francesca, Pistorio Angela, Guariento Andressa, Caorsi Roberta, Consolaro Alessandro, Gattorno Marco, Ravelli Angelo The Journal of rheumatology. 2019 04; 46(04):416-421. doi: 10.3899/jrheum.180331. pii: .
Treatment of juvenile idiopathic arthritis: what's new? Giancane Gabriella, Ruperto Nicolino, Current opinion in rheumatology. 2019 09; 31(09):428-435. doi: 10.1097/BOR.0000000000000632. pii: .
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Ter Haar Nienke M, van Dijkhuizen E H Pieter, Swart Joost F, van Royen-Kerkhof Annet, El Idrissi Ayman, Leek Arjen P, de Jager Wilco, de Groot Mark C H, Haitjema Saskia, Holzinger Dirk, Foell Dirk, van Loosdregt Jorg, Wulffraat Nico M, de Roock Sytze, Vastert Sebastiaan J Arthritis & rheumatology (Hoboken, N.J.). 2019 07; 71(07):1163-1173. doi: 10.1002/art.40865. pii: .
[New drugs for treatment of juvenile idiopathic arthritis]. Horneff Gerd Zeitschrift fur Rheumatologie. 2019 Sep; 78(Sep):587-598. doi: 10.1007/s00393-019-0646-3. pii: .
[New therapy approaches, better outcomes? : Results from inception cohorts for patients with juvenile idiopathic arthritis]. Sengler C Zeitschrift fur Rheumatologie. 2019 Sep; 78(Sep):610-619. doi: 10.1007/s00393-019-0648-1. pii: .
Nenhuma revista foi definida para este congresso.